PL404176A1 - Zastosowanie bakteriofagów - Google Patents

Zastosowanie bakteriofagów

Info

Publication number
PL404176A1
PL404176A1 PL404176A PL40417613A PL404176A1 PL 404176 A1 PL404176 A1 PL 404176A1 PL 404176 A PL404176 A PL 404176A PL 40417613 A PL40417613 A PL 40417613A PL 404176 A1 PL404176 A1 PL 404176A1
Authority
PL
Poland
Prior art keywords
hadv
preparation
bacteriophages
ameliorating
adenovirus
Prior art date
Application number
PL404176A
Other languages
English (en)
Other versions
PL232951B1 (pl
Inventor
Renata Zahorska
Maciej Przybylski
Jan Borysowski
Andrzej Górski
Original Assignee
Warszawski Uniwersytet Medyczny
Instytut Immunologii I Terapii Doświadczalnej Im. Ludwika Hirszfelda Polskiej Akademii Nauk We Wrocławiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny, Instytut Immunologii I Terapii Doświadczalnej Im. Ludwika Hirszfelda Polskiej Akademii Nauk We Wrocławiu filed Critical Warszawski Uniwersytet Medyczny
Priority to PL404176A priority Critical patent/PL232951B1/pl
Priority to EP14741948.5A priority patent/EP3003333B1/en
Priority to PCT/IB2014/061922 priority patent/WO2014195871A1/en
Priority to ES14741948.5T priority patent/ES2656191T3/es
Priority to US14/895,541 priority patent/US9850467B2/en
Publication of PL404176A1 publication Critical patent/PL404176A1/pl
Publication of PL232951B1 publication Critical patent/PL232951B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Ujawniono zastosowanie szczepu bakteriofagowego do wytwarzania preparatu do poprawiania stanu zdrowia pacjentów zainfekowanych adenowirusem, przy czym korzystnie wytwarzany preparat służy do leczenia lub zapobiegania infekcjom adenowirusowym, zwłaszcza wywołanym przez HAdV, korzystnie HAdV-5.
PL404176A 2013-06-03 2013-06-03 Zastosowanie bakteriofaga T4 PL232951B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL404176A PL232951B1 (pl) 2013-06-03 2013-06-03 Zastosowanie bakteriofaga T4
EP14741948.5A EP3003333B1 (en) 2013-06-03 2014-06-03 T4 phage for use in treating adenoviral infection caused by hadv
PCT/IB2014/061922 WO2014195871A1 (en) 2013-06-03 2014-06-03 Use of bacteriophages
ES14741948.5T ES2656191T3 (es) 2013-06-03 2014-06-03 Fago T4 para uso en el tratamiento de infección adenovírica causada por HAdV
US14/895,541 US9850467B2 (en) 2013-06-03 2014-06-03 Methods of using T4 bacteriophage in treatment of adenoviral infections caused by HAdV-5

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL404176A PL232951B1 (pl) 2013-06-03 2013-06-03 Zastosowanie bakteriofaga T4

Publications (2)

Publication Number Publication Date
PL404176A1 true PL404176A1 (pl) 2014-12-08
PL232951B1 PL232951B1 (pl) 2019-08-30

Family

ID=51212891

Family Applications (1)

Application Number Title Priority Date Filing Date
PL404176A PL232951B1 (pl) 2013-06-03 2013-06-03 Zastosowanie bakteriofaga T4

Country Status (5)

Country Link
US (1) US9850467B2 (pl)
EP (1) EP3003333B1 (pl)
ES (1) ES2656191T3 (pl)
PL (1) PL232951B1 (pl)
WO (1) WO2014195871A1 (pl)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115385D0 (en) * 2001-06-22 2001-08-15 Regma Biotechnologies Ltd Novel preparation
PL354822A1 (pl) 2002-06-30 2004-01-12 Instytut Immunologii i Terapii Doświadczalnej PANwe Wrocławiu Sposób otrzymywania oczyszczonych preparatów bakteriofagowych oraz nowe zastosowania polisacharydu lub jego estryfikowanej pochodnej
PL195437B1 (pl) 2001-07-18 2007-09-28 Inst Immunologii I Terapii Dos Sposób przygotowania poliwalentnych preparatów fagowych do leczenia zakażeń bakteryjnych
PL195815B1 (pl) * 2002-08-05 2007-10-31 Inst Immunologii I Terapii Dos Sposób otrzymywania szczepu bakteriofaga o zwiększonym powinowactwie do komórek eukariotycznych, środki go zawierające i zastosowania bakteriofagów
JP2007204415A (ja) * 2006-02-01 2007-08-16 Tokyo Institute Of Technology ファージ頭殻提示腸管免疫誘導型ワクチン
PL215522B1 (pl) * 2008-09-29 2013-12-31 Inst Immunologii I Terapii Doswiadczalnej Pan Nowe szczepy bakteriofagów do leczenia zakazen bakteryjnych, zwlaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
PL216091B1 (pl) * 2010-10-18 2014-02-28 Univ Wroclawski Nowe szczepy bakteriofagów do leczenia zakażeń bakteryjnych, zwłaszcza szczepami bakterii lekoopornych z rodzaju Klebsiella

Also Published As

Publication number Publication date
WO2014195871A1 (en) 2014-12-11
ES2656191T3 (es) 2018-02-26
PL232951B1 (pl) 2019-08-30
EP3003333B1 (en) 2017-10-18
EP3003333A1 (en) 2016-04-13
US9850467B2 (en) 2017-12-26
US20160122725A1 (en) 2016-05-05

Similar Documents

Publication Publication Date Title
JOP20200011B1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
PH12017500207A1 (en) Indoles for use in influenza virus infection
IN2015DN01156A (pl)
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
JP2015503422A5 (pl)
PH12017500393A1 (en) Pyrrolopyrimidines for use in influenza virus infection
IN2013MU01749A (pl)
PH12016500492B1 (en) Pyridazinone compounds and uses thereof
PH12016501122A1 (en) Delayed release compositions of linaclotide
PH12016501968A1 (en) Novel macrocyclic compounds
EA201890186A1 (ru) Применение штаммов микробактерий для получения антибактериальных агентов
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
CL2018000290A1 (es) Antagonistas del receptor de cgrp
HUE062482T2 (hu) Lactobacillus reuteri- és citráttartalmú készítmény gyógyászati felhasználásra
BR112017002675A2 (pt) métodos para aperfeiçoar desempenho miocárdico em pacientes de fontan com o uso de composições de udenafila
MX2017002093A (es) Terapia con anticuerpos para vih como sustituto de tratamiento.
PH12015502703A1 (en) Pharmaceutical compositions
MX2016004961A (es) Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
IN2014KN02584A (pl)
PH12016501127A1 (en) Adenosine a1 agonists as medicaments against renal diseases
PH12015502304A1 (en) Use of pidotimod to treat irritable bowel syndrome
PH12015502305A1 (en) Use of pidotimod to treat inflammatory bowel disease
TWD179054S (zh) 線圈零件